Alnylam Pharmaceuticals (NASDAQ:ALNY) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research report sent to investors on Wednesday morning,Benzinga reports. HC Wainwright currently has a $510.00 target price on the biopharmaceutical company’s stock.

ALNY has been the subject of a number of other research reports. Wall Street Zen lowered shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 14th. Royal Bank Of Canada dropped their price target on shares of Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating for the company in a research note on Tuesday, January 20th. Canaccord Genuity Group boosted their price objective on shares of Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the stock a “buy” rating in a research note on Tuesday. Weiss Ratings raised Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Thursday, January 15th. Finally, Truist Financial cut their target price on Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating on the stock in a report on Thursday, January 8th. Twenty-two analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $477.96.

Alnylam Pharmaceuticals Stock Up 0.0%

Shares of ALNY opened at $332.68 on Wednesday. Alnylam Pharmaceuticals has a 52 week low of $205.87 and a 52 week high of $495.55. The stock has a market capitalization of $44.12 billion, a price-to-earnings ratio of 194.55 and a beta of 0.35. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.71 and a current ratio of 2.76. The stock has a fifty day moving average of $369.58 and a 200-day moving average of $423.61.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $0.82 earnings per share for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.61). The firm had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.16 billion. Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The company’s revenue was up 84.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.65) EPS. As a group, sell-side analysts anticipate that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,959 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of $310.08, for a total value of $607,446.72. Following the completion of the sale, the executive vice president directly owned 31,769 shares in the company, valued at approximately $9,850,931.52. The trade was a 5.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 2,041 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $331.96, for a total value of $677,530.36. Following the completion of the transaction, the executive vice president directly owned 21,264 shares in the company, valued at approximately $7,058,797.44. This trade represents a 8.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 36,578 shares of company stock valued at $12,416,105 over the last ninety days. Insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Root Financial Partners LLC acquired a new position in Alnylam Pharmaceuticals during the third quarter worth $25,000. Salomon & Ludwin LLC bought a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth about $27,000. HM Payson & Co. acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth about $27,000. Golden State Wealth Management LLC lifted its position in Alnylam Pharmaceuticals by 100.0% in the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 36 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new position in Alnylam Pharmaceuticals during the 3rd quarter valued at about $29,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals News Roundup

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reaffirmed a “buy” on ALNY and set a $510 price target, implying substantial upside vs. current levels — a strong analyst vote of confidence for growth expectations. Read More.
• Positive Sentiment: Canaccord Genuity raised its price target from $415 to $429 and kept a “buy” rating, supporting near‑term buyer interest. Read More.
• Positive Sentiment: Freedom Capital Markets upgraded ALNY (reported via MSN), and a Motley Fool piece highlighted an influential pundit upgrade that helped lift momentum earlier in the week — both items can attract more buying. Read More. · Read More.
• Neutral Sentiment: Valuation commentary: a Yahoo Finance piece framed Alnylam’s valuation as mixed — models show bullish fair‑value scenarios but recent returns are uneven; useful context for longer‑term investors rather than an immediate catalyst. Read More.
• Neutral Sentiment: Reported short‑interest figures in the feed show zero/NaN values and a 0.0 days‑to‑cover metric — this appears to be a data/reporting artifact and should be treated as non‑actionable until exchange‑confirmed. (No reliable link available.)
• Negative Sentiment: Multiple insider sales were disclosed this week that could pressure sentiment: CEO Yvonne Greenstreet sold 6,958 shares (~$310 avg) and several EVPs (including Kevin Fitzgerald, Jeffrey Poulton, Tolga Tanguler, Pushkal Garg) sold shares in mid‑thousands at ~$310–332 — large insider liquidity events can be perceived negatively by investors. Read More. · Read More.
• Negative Sentiment: Some sell‑side pressure: Chardan trimmed a price target to $425 and other brokers (e.g., Morgan Stanley, Wells Fargo) have lowered targets or applied neutral/equal‑weight ratings earlier — mixed analyst views add volatility risk vs. unanimous buy signals. Read More.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.